

NOXXON PHARMA AG TO PRESENT AT SACHS ASSOCIATES 6th ANNUAL BIOTECH IN EUROPE INVESTOR FORUM IN ZURICH, SWITZERLAND, OCTOBER 4, 2006

Berlin, Germany, September 29, 2006 -- NOXXON Pharma AG (NOXXON), the next generation aptamer company and leader in Spiegelmer therapeutics, will present at Sachs Associates 6th Annual Biotech in Europe Investor Forum in Zurich, Switzerland. The presentation is scheduled for October 4 at 03:35 pm in the Basel Room of the Swissôtel Zurich as part of the Sector Workshop 'Therapeutics'.

Dr. Sven Klussmann, Chief Executive and Chief Scientific Officer of NOXXON, will provide a corporate overview of NOXXON, including the current status of development of the company's next generation aptamers. NOXXON is currently assembling investors for a series C round of financing to support the pre-clinical and clinical development of NOXXON's lead compounds NOX-A12 for the treatment of diabetic retinopathy and NOX-E36 for the treatment of renal inflammation.

About the event:

Sachs Associates Annual Biotech in Europe Investor Forum is one of Europe's leading events to assemble representatives of emerging companies and key members of the world's investment community in order to explore investment opportunities. For more information or a schedule of presentations visit: www.sachsforum.com/zurich06.html.

About NOXXON Pharma AG, the next generation aptamer company:

Based on one of the largest and best protected patent portfolio, Berlin-based NOXXON Pharma AG develops biostable aptamers, novel substances based on mirror image nucleic acids. These so-called Spiegelmers® (the German word "Spiegel" means mirror) bind highly specific to the pharmacologically relevant target for which they were selected. Thanks to their structural characteristics, Spiegelmers® are extremely resistant to degradation and not immunogenic - a new generation of improved therapeutics.

Website info: <http://www.noxxon.net>

General contact: Esther Hildebrandt
NOXXON Pharma AG
Max-Dohrn-Strasse 8-10
10589 Berlin, Germany
Phone: + 49 30 72 62 47 0
FAX: + 49 30 72 62 47 225
Email: ehildebrandt@noxxon.net